Emerging trials combining PI3K/mTOR inhibitors or glutaminase blockers (CB-839) with conventional chemotherapy in KEAP1-mutant non-small-cell lung cancer exemplify how mechanistic insights are being translated into clinical strategies [84]. The gene discussed is GLS; the disease is non-small cell lung carcinoma.